Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
Clinical trial NCT02325791 · COMPLETED
Trial details
- NCT number
- NCT02325791
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-21
- Primary completion
- 2017-07-05
- Enrollment
- 1177
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.